Vantage logo

Close encounters of the Serd kind

All-comer Serd studies in pretreated breast cancer look doomed, so why do Astra and Lilly persist? And why isn’t Radius seizing its advantage?

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.